{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:18:16Z","timestamp":1773364696665,"version":"3.50.1"},"reference-count":54,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,3,22]]},"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This is a retrospective observational study focusing on the utilisation of statins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan\u2019s National Health Insurance Research Database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity\/moderate-intensity\/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of statin users increased from 10\u2009299 (~1.4% of adults) in 2002 to 50\u2009687 (~6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%\u201336.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007\u20132011. Selection of statins did not differ between people with versus without history of myopathy or liver injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Atorvastatin was the most commonly used statin in Taiwan during 2002\u20132011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2016-014150","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T23:05:19Z","timestamp":1501023919000},"page":"e014150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan\u2019s National Health Insurance Research Database"],"prefix":"10.1136","volume":"7","author":[{"given":"Hsing-Chun","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason C","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Y","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"key":"2024051611564183000_7.5.e014150.1","unstructured":"WHO. Cardiovascular diseases (CVDs). 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/ (accessed 3 Apr, 2015)."},{"key":"2024051611564183000_7.5.e014150.2","unstructured":"Statistics of causes of death. Taiwan: Ministry of Health and Welfare, 2015."},{"key":"2024051611564183000_7.5.e014150.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200073024"},{"key":"2024051611564183000_7.5.e014150.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"2024051611564183000_7.5.e014150.5","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095214"},{"key":"2024051611564183000_7.5.e014150.6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"2024051611564183000_7.5.e014150.7","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"2014","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"2024051611564183000_7.5.e014150.8","unstructured":"NICE Clinical Guideline 181. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014. London: National Clinical Guideline Centre, 2014."},{"key":"2024051611564183000_7.5.e014150.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"2024051611564183000_7.5.e014150.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2024051611564183000_7.5.e014150.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2024051611564183000_7.5.e014150.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.2.207"},{"key":"2024051611564183000_7.5.e014150.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019014"},{"key":"2024051611564183000_7.5.e014150.14","unstructured":"Pharmaceutical Benefit and Reimbursement Scheme. . National Health Insurance Administration,\u00a0Ministry of Health and Welfare, Taiwan, 2016."},{"key":"2024051611564183000_7.5.e014150.15","unstructured":"IMS Institute for Healthcare Informatics. Top 20 global therapy areas 2014. England and Wales: IMS Health MIDAS, 2014."},{"key":"2024051611564183000_7.5.e014150.16","unstructured":"IMS institute for healthcare informatics. The global use of medicines: outlook through 2016. USA: \u00a0IMS Institute for Healthcare Informatics, 2012."},{"key":"2024051611564183000_7.5.e014150.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281348"},{"key":"2024051611564183000_7.5.e014150.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02478.x"},{"key":"2024051611564183000_7.5.e014150.19","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.4.417"},{"key":"2024051611564183000_7.5.e014150.20","unstructured":"Lin M-J . The dyslipidemia drugs use in Taiwan. Taiwan: Kaohsiung Medical University, 2005."},{"key":"2024051611564183000_7.5.e014150.21","unstructured":"Wung D-C . Drug utilization evaluation and therapeutic equivalence of statins. Taiwan: National Cheng Kung University,, 2007."},{"key":"2024051611564183000_7.5.e014150.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"2024051611564183000_7.5.e014150.23","first-page":"483","article-title":"The PCSK9 inhibitors: a novel therapeutic target enters clinical practice","volume":"8","author":"Lepor","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2024051611564183000_7.5.e014150.24","first-page":"149573","article-title":"Effects of adherence to statin therapy on health care outcomes and utilizations in Taiwan: a Population-Based study","volume":"2015","author":"Li","year":"2015","journal-title":"Biomed Res Int"},{"key":"2024051611564183000_7.5.e014150.25","unstructured":"National health insurance annual report 2014-2015. 2014 http:\/\/nhird.nhri.org.tw\/en\/index.htm (accessed 6 Sep, 2015)."},{"key":"2024051611564183000_7.5.e014150.26","unstructured":"National health insurance reseach database. http:\/\/nhird.nhri.org.tw\/en\/Data_Subsets.html (accessed 6 Sep, 2015)."},{"key":"2024051611564183000_7.5.e014150.27","unstructured":"ATC 2011. http:\/\/www.whocc.no\/atc\/structure_and_principles\/ (accessed 13 Sep, 2015)"},{"key":"2024051611564183000_7.5.e014150.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.088"},{"key":"2024051611564183000_7.5.e014150.29","unstructured":"International classification of diseases ninth revision, clinical modification (ICD-9-CM). (accessed 6 Sep, 2015)."},{"key":"2024051611564183000_7.5.e014150.30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pds.3470","article-title":"Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration\u2019s Mini-Sentinel Distributed Database","volume":"22","author":"Lo Re","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024051611564183000_7.5.e014150.31","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.852848"},{"key":"2024051611564183000_7.5.e014150.32","doi-asserted-by":"publisher","DOI":"10.1177\/2047487314525531"},{"key":"2024051611564183000_7.5.e014150.33","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr158"},{"key":"2024051611564183000_7.5.e014150.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.06.010"},{"key":"2024051611564183000_7.5.e014150.35","first-page":"711","article-title":"Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity","volume":"83","author":"Gillett","year":"2011","journal-title":"Am Fam Physician"},{"key":"2024051611564183000_7.5.e014150.36","unstructured":"Cheng CL . Pharmacoepidemiologic Research for Ischemic Stroke in Elderly Patients Who Taking Cyclo-oxygenase-2 inhibitors or Conventional Non-steroidal Anti-inflammatory Drugs (PhD Dissertation). Taiwan: National Cheng Kung University, 2010."},{"key":"2024051611564183000_7.5.e014150.37","unstructured":"J-W W . Prescribing patterns and safety of HMG-CoA reductase inhibitors usage within national health insurance research database: a Drug-Interaction approach. Master Thesis. National Taiwan University, 2005."},{"key":"2024051611564183000_7.5.e014150.38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/pds.3646","article-title":"Statins and the risk of liver injury: a population-based case-control study","volume":"23","author":"Chen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024051611564183000_7.5.e014150.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102146","article-title":"Pattern of statin use in southern italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?","volume":"9","author":"Ferrajolo","year":"2014","journal-title":"PLoS One"},{"key":"2024051611564183000_7.5.e014150.40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S78145","article-title":"Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a danish population-based study","volume":"7","author":"Svensson","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2024051611564183000_7.5.e014150.41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CLEP.S104258","article-title":"Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the health improvement network primary care data","volume":"8","author":"O\u2019Keeffe","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2024051611564183000_7.5.e014150.42","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0239-3"},{"key":"2024051611564183000_7.5.e014150.43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/11537330-000000000-00000","article-title":"Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study","volume":"27","author":"Geleedst-De Vooght","year":"2010","journal-title":"Drugs Aging"},{"key":"2024051611564183000_7.5.e014150.44","doi-asserted-by":"publisher","DOI":"10.1177\/2047487313480435"},{"key":"2024051611564183000_7.5.e014150.45","unstructured":"Purvis L . Rx price watch case study: efforts to reduce the impact of generic competition for\u00a0lipitor: grey literature report. 2013."},{"key":"2024051611564183000_7.5.e014150.46","unstructured":"Smith MEB , Lee MEB , Haney MEB , et al . Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. Portland (OR: Oregon Health & Science University, 2009. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/21089253."},{"key":"2024051611564183000_7.5.e014150.47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2024051611564183000_7.5.e014150.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2024051611564183000_7.5.e014150.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800742"},{"key":"2024051611564183000_7.5.e014150.50","first-page":"18","article-title":"A retrospective study of statin use and its effectiveness in Taiwanese","volume":"25","author":"Chin-Feng Hsuan","year":"2009","journal-title":"Acta Cardiologica Sinica"},{"key":"2024051611564183000_7.5.e014150.51","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"2024051611564183000_7.5.e014150.52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-85"},{"key":"2024051611564183000_7.5.e014150.53","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005429","article-title":"Statins and risk for new-onset diabetes mellitus: a real-world cohort study using a clinical research database","volume":"95","author":"Yoon","year":"2016","journal-title":"Medicine"},{"key":"2024051611564183000_7.5.e014150.54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-014150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T19:17:02Z","timestamp":1715887022000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-014150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,17]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1136\/bmjopen-2016-014150"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-014150","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}